Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)

Inclusion Criteria: * Age: 21-75 * Body Mass Index (BMI) \>19 kg/m\^2 * Subjects with biopsy/MRE proven NASH \[MRE liver fat ≥ 5%, with elevated liver enzymes ALT \<5x upper limit normal (ULN)\]. * Subjects with NAFLD and MRE shows F0 or greater fibrosis * Subjects with history suggestive of NAFLD/NASH * Total bilirubin must be \< 1.5 x ULN and INR must be \< 1.3 at baseline screening. * TSH and CPK will be within normal limits (WNL) at screening. * Subjects with type 2 diabetes who are on stable doses of medications (except pioglitazone) to control hyperglycemia and have baseline HbA1c of 10% or lower. * Hemoglobin must be greater than or equal to 12.0 in males and 11.0 in females. Exclusion Criteria: * Medications that may affect glucose metabolism such as corticosteroids, opiates, barbiturates, and anticoagulants. * Subjects with anemia, and symptoms suggestive of undiagnosed illness, overt hepatic disease, stroke, Alzheimer's disease, autoimmune hepatitis, alcoholism or increased alcohol consumption over the American Diabetes Association (ADA) guidelines. * Any disorder that may potentially impact the outcome measures. * Pregnant women and children. * Subjects planning weight loss or in any weight loss program. * Subjects taking TZD's, Atazanavir, Indinavir, Ketoconazole, Valproic acid, Silybum marianum and Valeriana officinalis.